We are live on ! Find out more
ARNA

Arena Pharmaceuticals Inc

Delisted

ARNA was delisted on the 10th of March, 2022.

184 hedge funds and large institutions have $1.88B invested in Arena Pharmaceuticals Inc in 2019 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 60 increasing their positions, 53 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more call options, than puts

Call options by funds: $21.7M | Put options by funds: $12.1M

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

27% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 26

23% more capital invested

Capital invested by funds: $1.53B → $1.88B (+$352M)

13% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 53

4% more funds holding

Funds holding: 177184 (+7)

Holders
184
Holders Change
+7
Holders Change %
+3.95%
% of All Funds
3.98%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.06%
New
33
Increased
60
Reduced
53
Closed
26
Calls
$21.7M
Puts
$12.1M
Net Calls
+$9.6M
Net Calls Change
+$13.1M
Name Holding Trade Value Shares
Change
Change in
Stake
IRC
176
Investors Research Corp
Georgia
$2K +$2.29K +50 New
BCA
177
Berman Capital Advisors
Georgia
$1K
TFS
178
TrustCore Financial Services
Tennessee
$1K
US Bancorp
179
US Bancorp
Minnesota
$1K
SHIM
180
Stone House Investment Management
Pennsylvania
$1K +$826 +18 New
GSWM
181
Golden State Wealth Management
California
$1K +$1.38K +30 New
TRCT
182
Tower Research Capital (TRC)
New York
$1K +$1.47K +32 New
VCM
183
Versant Capital Management
Arizona
$1K +$1.93K +42 New
CCM
184
Camber Capital Management
Massachusetts
-$19.5M -500,000 Closed
EMG
185
ETF Managers Group
New Jersey
-$12.3M -316,684 Closed
Point72 Asset Management
186
Point72 Asset Management
Connecticut
-$10.7M -275,100 Closed
Group One Trading
187
Group One Trading
Illinois
-$2.53M -55,092 Closed
Renaissance Technologies
188
Renaissance Technologies
New York
-$2.04M -52,368 Closed
CC
189
Carlson Capital
Texas
-$1.78M -45,783 Closed
Millennium Management
190
Millennium Management
New York
-$1.17M -30,148 Closed
TRAM
191
Tuscan Ridge Asset Management
Illinois
-$1M -25,795 Closed
SEC
192
Seven Eight Capital
New York
-$460K -11,800 Closed
Balyasny Asset Management
193
Balyasny Asset Management
Illinois
-$358K -9,179 Closed
ARTA
194
A.R.T. Advisors
New York
-$250K -6,429 Closed
Canada Life
195
Canada Life
Manitoba, Canada
-$231K -6,152 Closed
TI
196
Trexquant Investment
Connecticut
-$236K -6,047 Closed
PP
197
Paloma Partners
Connecticut
-$235K -6,016 Closed
Simplex Trading
198
Simplex Trading
Illinois
-$242K -5,281 Closed
Russell Investments Group
199
Russell Investments Group
United Kingdom
-$204K -5,244 Closed
Walleye Trading
200
Walleye Trading
New York
-$240K -5,236 Closed

ARNA Hedge Fund Activity: Q1 2019 in Review

184 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Arena Pharmaceuticals Inc (ARNA) for Q1 2019, worth a combined $1.88B — up 23% from $1.53B a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new ARNA positions and 26 closed out — a net gain of 7 holders — while 60 added to existing stakes and 53 trimmed.

The largest buyer was Eagle Asset Management, opening a new position worth an estimated $43.1M. The largest seller was Camber Capital Management, exiting entirely with an estimated $19.5M sold.

  • 184 institutional investors held Arena Pharmaceuticals Inc (ARNA) as of Q1 2019, up from 177 in Q4 2018.
  • Funds reported $1.88B of Arena Pharmaceuticals Inc stock for Q1 2019, up 23% quarter-over-quarter.
  • 33 funds opened new Arena Pharmaceuticals Inc positions in Q1 2019 and 26 closed out, a net change of +7 holders.
  • The largest Arena Pharmaceuticals Inc buyer in Q1 2019 was Eagle Asset Management, an estimated $43.1M added.
  • The largest Arena Pharmaceuticals Inc seller in Q1 2019 was Camber Capital Management, an estimated $19.5M sold.

Based on aggregated 13F filings for Q1 2019.